Dr. Reddy’s Laboratories launches sorafenib generic in US
Dr. Reddy’s Laboratories said that it has launched Dr. Reddy’s Sorafenib Tablets, USP, 200 mg in the US market following the approval of the US Food and Drug Administration (FDA).
Dr. Reddy’s Sorafenib Tablets, USP, 200 mg is a generic of Bayer HealthCare Pharmaceuticals’ cancer drug Nexavar (sorafenib). The product will be available in 200 mg tablets in bottle count sizes of 120, said Dr. Reddy’s Laboratories.
Dr. Reddy’s Laboratories launches sorafenib generic in US. Photo courtesy of Karthikndr/Wikimedia Commons.
Marc Kikuchi — Dr. Reddy’s Laboratories North America Generics CEO said: “We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients.”